Provided by Tiger Trade Technology Pte. Ltd.

Ionis Pharmaceuticals

44.84
-2.4100-5.10%
Pre-market: 45.240.4000+0.89%08:19 EDT
Volume:7.96M
Turnover:363.93M
Market Cap:7.45B
PE:-12.89
High:47.59
Open:47.38
Low:44.66
Close:47.25
52wk High:86.74
52wk Low:44.66
Shares:166.18M
Float Shares:161.92M
Volume Ratio:1.89
T/O Rate:4.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4800
EPS(LYR):-2.3812
ROE:-105.50%
ROA:-12.42%
PB:16.95
PE(LYR):-18.83

Loading ...

Ionis adds former Alexion CEO Ludwig Hantson to board

Reuters
·
Jun 09

BRIEF-Ionis Announces Appointment Of Ludwig Hantson, Ph.D. To Board Of Directors

Reuters
·
Jun 08

Ionis Announces Appointment of Ludwig Hantson, Ph.d. to Board of Directors

THOMSON REUTERS
·
Jun 08

Ionis Pharmaceuticals (IONS) Receives a Buy from Guggenheim

TIPRANKS
·
Jun 06

Ionis posts presentation for 2026 annual shareholders meeting

Reuters
·
Jun 05

Ionis director Spencer R. Berthelsen disposes of 8,000 common shares for $605,360

Reuters
·
Jun 04

Ionis Pharmaceuticals Price Target Maintained With a $125.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 01

Ionis Pharmaceuticals: Advancing Pipeline, HBV Phase III Success, and Robust Catalyst Flow Underpin Buy Rating

TIPRANKS
·
May 28

Ionis partner GSK reports B-Well 1, B-Well 2 trials meet primary endpoint

TIPRANKS
·
May 28

Ionis Partner GSK Announces Bepirovirsen Achieves Unprecedented Functional Cure Rates With Potential to Redefine Treatment for Chronic Hepatitis B

THOMSON REUTERS
·
May 28

A New, Powerful Cholesterol-Lowering Drug Is on the Horizon -- WSJ

Dow Jones
·
May 28

U.S. RESEARCH ROUNDUP-CAVA Group, Eagle Materials, Vertiv

Reuters
·
May 20

J.P. Morgan Sticks to Their Buy Rating for Ionis Pharmaceuticals (IONS)

TIPRANKS
·
May 20

Ionis Pharmaceuticals Initiated at Buy by Citigroup

Dow Jones
·
May 19

Ionis Pharmaceuticals initiated with a Buy, named a top pick at Citi

TIPRANKS
·
May 19

Assessing Ionis Pharmaceuticals (IONS) Valuation As Shares Cool After A Multi Year Run

Simply Wall St.
·
May 16

Ionis CEO Brett P. Monia disposes of USD 361,478 common shares

Reuters
·
May 16

Ionis Pharmaceuticals participates in a conference call with Cantor

TIPRANKS
·
May 15

BRIEF-Ionis Partner Biogen Announces Topline Results From Phase 2 Celia Study Of Diranersen

Reuters
·
May 14

Ionis Partner Biogen Announces Topline Results From Phase 2 Celia Study of Diranersen (Biib080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients With Early Alzheimer’s Disease

THOMSON REUTERS
·
May 14